Treatment of Cerebral Venous Thrombosis During Pregnancy or Puerperium
Cerebral venous thrombosis (CVT) occurring during pregnancy or in the puerperium (the period following delivery) presents a distinct clinical challenge: the obstetric context directly constrains which anticoagulant agents can be safely used and shapes how treatment must be structured across the pregnancy and postpartum periods.
Clinical Scenario
This protocol applies to female patients who develop CVT during pregnancy or in the puerperium. Pregnancy and recent delivery are the defining features of this presentation, as they fundamentally alter the safety profile of available anticoagulant options.
Treatment Approach
Anticoagulation is the cornerstone of management in this population, with agent selection strictly guided by pregnancy and postpartum status — certain anticoagulant classes are contraindicated at specific stages.
The complete regimen — covering postpartum agent selection, transition criteria, and treatment duration — is detailed in the full structured protocol.
References
DOI: 10.1161/STR.0000000000000456
- Therefore, anticoagulation for CVT during pregnancy and early in the puerperium consists of LMWH in the majority of women.
- For women with CVT during pregnancy, LMWH in full anticoagulant doses should be continued throughout pregnancy, and LMWH or VKA with a target international normalized ratio of 2.0 to 3.0 should be continued for at least 6 weeks postpartum (for a total minimum duration of therapy of 3 months).
- DOACs are not suitable in women who are pregnant (both DOAC and warfarin are contraindicated; only LMWH is recommended) or breastfeeding (DOACs are contraindicated; Figure 4).